Analyst Price Target is C$10.28
▲ +157.08% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for HLS Therapeutics in the last 3 months. The average price target is C$10.28, with a high forecast of C$17.50 and a low forecast of C$4.35. The average price target represents a 157.08% upside from the last price of C$4.00.
Current Consensus is
The current consensus among 4 contributing investment analysts is to hold stock in HLS Therapeutics. This Hold consensus rating has held steady for over two years.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.